



Supplemental Figure 6.

A, Proliferation assay performed on 786-O cells grown in media with 10%FBS and treated with the SCARB1 inhibitor, BLT-1 (5mM), or vehicle control (DMSO). **B**, Annexin-V/PI staining and flow cytometry analysis performed on 786-O cells after 96h of BLT-1 treatment (5mM). **C**, Cell cycle analysis for 786-O cells after 96h of BLT-1 treatment (5mM) showing increased cell cycle arrest in G1 when SCARB1 is inhibited. **D**, HDL uptake assay using BLT-1-treated (96h, 5mM) 786-O cells showing reduced HDL uptake when SCARB1 is inhibited. **E**, Representative photographs of 786-O cells grown in media supplemented with 10% FBS, 10% DLPS, or 10% DLPS and HDL (100mg/mL) and treated with BLT-1 (5mM) or DMSO for 96h. Magnification (100X). **F**, Proliferation assay performed on 786-O cells grown in media with 10%FBS or 10% DLPS media supplemented with or without HDL (100mg/mL) and treated with BLT-1 (5mM) or vehicle control (DMSO). **G**, Annexin-V/PI staining and flow cytometry analysis performed on 786-O cells after 96h of DMSO or BLT-1 treatment (5mM) and grown in 10% FBS or 10% DLPS media supplemented with or without HDL (100mg/mL). **H**, Cell cycle analysis for 786-O cells after 96h of BLT-1 (5mM) or DMSO treatment and grown in 10% FBS or 10% DLPS media supplemented with or without HDL (100mg/mL). Percentage of cells in G1, S and G2-M phases is displayed. (All experiments were performed in at least triplicates and statistical analysis was applied with $*=P<0.05$, $**=P<0.01$, $***=<0.001$, n.s=non-significant). **I**, Representative photographs of A498 tumors grown in nude mice treated or not with BLT-1 (50 mg/kg) by oral gavage daily for 30 days.